U.S. Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Primary Immunodeficiency, Chronic Inflammatory, Demyelinating Polyradiculoneuropathy, Congenital AIDS), By Distribution Channels(Hospital Pharmacy, Specialty Pharmacy, others), By Region - Industry Forecast 2025-2032

U.S. Intravenous Immunoglobulin Market size was valued at USD 6.24 Billion in 2023 and is poised to grow from USD 6.73 Billion in 2024 to USD 12.37 Billion by 2032, growing at a CAGR of 7.90% during the forecast period (2025-2032).

The need for immunoglobulin replacement therapy to treat Primary Immunodeficiency Diseases (PIDD) is rising, and this is one of the main drivers of the U.S. IVIG market.

Another key driver is the approval of new medicines, which is expanding the range of available treatments for patients. Adoption of home infusion therapy increased exponentially, which can be linked to the immunocompromised patients' weakened immunity and the safer administration of medications at home. Post-pandemic, the tendency is predicted to persist.

The COVID-19 pandemic has caused significant changes in the industry's market dynamics. Due to the increased demand for plasma products in the early stages of the pandemic for the treatment of SARS-CoV-2 patients, there was a scarcity of immunoglobulin products in the U.S. IVIG market.

The drop in plasma donations during the epidemic compounded this stress by placing a major strain on the plasma supply system. Because plasma fractionations take time, there were supply problems in the beginning of 2021.Businesses are looking into IGIV therapies as a possible kind of treatment.

Higher treatment adoption may result from approval in the following years. Immunoglobulin therapy is costly, which prevents the U.S. from using IVIG more widely. For Instance, according to NCBI, the typical session cost in the U.S. was roughly U.S.D 9,720, which equates to a monthly cost of USD 41,796 for 4.3 sessions.

Patients without insurance or Medicare may find it challenging to receive care because the average annual cost of treating a CIDP patient exceeds USD 136,000. Key manufacturers are putting more emphasis on getting new products approved and into the market in order to meet the growing demand from patients for IVIG due to the evolving needs of the patient population. Multiple autoimmune, neurological, haematological, and immunodeficiency illnesses are all treated with IVIG replacement therapy.

US Intravenous Immunoglobulin Market is poised to grow at a sustainable CAGR for the next forecast year.